Lexicon Pharmaceuticals Inc LXRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LXRX is a good fit for your portfolio.
News
-
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
-
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?
-
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
-
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin
-
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
-
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
-
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
-
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
Trading Information
- Previous Close Price
- $2.19
- Day Range
- $2.13–2.47
- 52-Week Range
- $0.92–3.79
- Bid/Ask
- $2.37 / $2.45
- Market Cap
- $590.97 Mil
- Volume/Avg
- 7.1 Mil / 4.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 440.77
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 285
- Website
- https://www.lexpharma.com
Comparables
Valuation
Metric
|
LXRX
|
TVTX
|
RETA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 37.91 |
Price/Book Value | 6.31 | 2.89 | 74.73 |
Price/Sales | 440.77 | 3.94 | 283.91 |
Price/Cash Flow | — | — | — |
Price/Earnings
LXRX
TVTX
RETA
Financial Strength
Metric
|
LXRX
|
TVTX
|
RETA
|
---|---|---|---|
Quick Ratio | 5.42 | 3.31 | 2.82 |
Current Ratio | 5.60 | 3.47 | 3.21 |
Interest Coverage | −13.11 | −34.10 | −1.31 |
Quick Ratio
LXRX
TVTX
RETA
Profitability
Metric
|
LXRX
|
TVTX
|
RETA
|
---|---|---|---|
Return on Assets (Normalized) | −68.99% | −2.68% | −51.74% |
Return on Equity (Normalized) | −130.40% | −12.41% | — |
Return on Invested Capital (Normalized) | −74.77% | −5.04% | −186.99% |
Return on Assets
LXRX
TVTX
RETA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nskhspgsb | Yswt | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wtrkwhh | Jypkb | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Svxhbvdw | Krmkplt | $105.6 Bil | |
MRNA
| Moderna Inc | Vhyrptfl | Srt | $40.8 Bil | |
ARGX
| argenx SE ADR | Nhfkvvyb | Yjkf | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Xxlblgzn | Lhc | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jxwxddxz | Hkjgz | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gmxlnddh | Nwrnw | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mncwmscrgn | Gcwkkhf | $13.6 Bil | |
INCY
| Incyte Corp | Hvhwqhgh | Spsmjd | $12.8 Bil |